Can Bostan Ozge, Damadoglu Ebru, Sarac Basak Ezgi, Kilic Busra, Sahiner Umit Murat, Karaaslan Cagatay, Karakaya Gul, Kalyoncu Ali Fuat
Hacettepe University Faculty of Medicine, Department of Chest Diseases, Division of Allergy and Immunology, Ankara, Turkey.
Hacettepe University Faculty of Science, Department of Biology, Molecular Biology Section, Ankara, Turkey.
Dermatol Pract Concept. 2023 Oct 1;13(4):e2023272. doi: 10.5826/dpc.1304a272.
Cytokines are key mediators in immunological and inflammatory conditions, including chronic spontaneous urticaria (CSU).
To investigate Th1, Th2, and Th17 cytokine profiles in CSU and to evaluate the possible effect of omalizumab treatment.
Patients who were followed up for CSU, as well as healthy volunteers, were included in the study. To assess urticaria activity, the 7-day-Urticaria Activity Score (UAS-7), the Urticaria Control Test (UCT), and the Chronic Urticaria Quality of Life Questionnaire (CU-QoL) were filled. Serum levels of IL-6, IL-17, IL-31, eotaxin, RANTES, TNF-α, and TSLP were analyzed by ELISA and compared in CSU and control groups. The patients were analyzed in two groups as the omalizumab group and the non-omalizumab group based on their treatment status.
Total IgE, ESR, CRP, RANTES, and TNF-a were significantly different in the overall comparison of the three groups: CSU-receiving omalizumab, CSU-not receiving omalizumab, and control groups (P <0.01, 0.015, <0.01, <0.01 and <0.01 respectively). Total IgE, CRP, RANTES, and TNF-α values were similar in those who received and did not receive omalizumab, yet these biomarkers were significantly higher in both groups than in the control group (P < 0.05). Statistical significance in ESR was observed only between the CSU-receiving omalizumab group and the control group (P = 0.01). Within the CSU patients, there was a slight but significant correlation between UCT and TNF-α (P = 0.008, r = 0.32) and IL-17 (P = 0.06, r = 0.33) levels.
The investigated cytokine profile in CSU patients may differ from healthy controls, particularly with the higher levels of RANTES and TNF-α, and omalizumab treatment does not seem to affect that profile in CSU patients.
细胞因子是免疫和炎症状态的关键介质，包括慢性自发性荨麻疹（CSU）。
研究CSU患者的Th1、Th2和Th17细胞因子谱，并评估奥马珠单抗治疗的可能效果。
纳入接受CSU随访的患者以及健康志愿者。为评估荨麻疹活动情况，填写7天荨麻疹活动评分（UAS-7）、荨麻疹控制试验（UCT）和慢性荨麻疹生活质量问卷（CU-QoL）。通过酶联免疫吸附测定法（ELISA）分析血清白细胞介素-6（IL-6）、白细胞介素-17（IL-17）、白细胞介素-31、嗜酸性粒细胞趋化因子、调节激活正常T细胞表达和分泌因子（RANTES）、肿瘤坏死因子-α（TNF-α）和胸腺基质淋巴细胞生成素（TSLP）水平，并在CSU组和对照组中进行比较。根据治疗状态将患者分为奥马珠单抗组和非奥马珠单抗组两组进行分析。
在接受奥马珠单抗治疗的CSU组、未接受奥马珠单抗治疗的CSU组和对照组这三组的总体比较中，总免疫球蛋白E（Total IgE）、红细胞沉降率（ESR）、C反应蛋白（CRP）、RANTES和TNF-α存在显著差异（分别为P<0.01、0.015、<0.01、<0.01和<0.01）。接受和未接受奥马珠单抗治疗的患者的Total IgE、CRP、RANTES和TNF-α值相似，但这两组这些生物标志物均显著高于对照组（P<0.05）。仅在接受奥马珠单抗治疗的CSU组和对照组之间观察到ESR有统计学意义（P = 0.01）。在CSU患者中，UCT与TNF-α水平（P = 0.008，r = 0.32）和IL-17水平（P = 0.06，r = 0.33）之间存在轻微但显著的相关性。
CSU患者中所研究的细胞因子谱可能与健康对照不同，尤其是RANTES和TNF-α水平较高，并且奥马珠单抗治疗似乎并未影响CSU患者的细胞因子谱。
